Evidence map›Paper›PMID 41278202›Full record

ReviewFrontiers in cell and developmental biology2025

Modeling neurodegenerative diseases with brain organoids: from development to disease applications.

Teresa Larriba-González, Marina García-Martín, Doddy Denise Ojeda-Hernández, Paula Rincón-Cerrada, Lucía Martín-Blanco, María Soledad Benito-Martín, Belén Selma-Calvo, Sarah de la Fuente-Martín, Jordi A Matias-Guiu, Jorge Matias-Guiu and 1 more

Abstract readReview
In one paragraph

Review in Frontiers in cell and developmental biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Teresa Larriba-González *Laboratory of Neurobiology and Advanced Therapies, Institute of Neurosciences, San Carlos Health Research Institute (IdISSC), Department of Neurology, San Carlos Clinical Hospital, Madrid, Spain.
Marina García-Martín *Laboratory of Neurobiology and Advanced Therapies, Institute of Neurosciences, San Carlos Health Research Institute (IdISSC), Department of Neurology, San Carlos Clinical Hospital, Madrid, Spain.
Doddy Denise Ojeda-HernándezLaboratory of Neurobiology and Advanced Therapies, Institute of Neurosciences, San Carlos Health Research Institute (IdISSC), Department of Neurology, San Carlos Clinical Hospital, Madrid, Spain.
Paula Rincón-CerradaLaboratory of Neurobiology and Advanced Therapies, Institute of Neurosciences, San Carlos Health Research Institute (IdISSC), Department of Neurology, San Carlos Clinical Hospital, Madrid, Spain.
Lucía Martín-BlancoLaboratory of Neurobiology and Advanced Therapies, Institute of Neurosciences, San Carlos Health Research Institute (IdISSC), Department of Neurology, San Carlos Clinical Hospital, Madrid, Spain.
María Soledad Benito-MartínLaboratory of Neurobiology and Advanced Therapies, Institute of Neurosciences, San Carlos Health Research Institute (IdISSC), Department of Neurology, San Carlos Clinical Hospital, Madrid, Spain.
Belén Selma-CalvoLaboratory of Neurobiology and Advanced Therapies, Institute of Neurosciences, San Carlos Health Research Institute (IdISSC), Department of Neurology, San Carlos Clinical Hospital, Madrid, Spain.
Sarah de la Fuente-MartínLaboratory of Neurobiology and Advanced Therapies, Institute of Neurosciences, San Carlos Health Research Institute (IdISSC), Department of Neurology, San Carlos Clinical Hospital, Madrid, Spain.
Jordi A Matias-GuiuLaboratory of Neurobiology and Advanced Therapies, Institute of Neurosciences, San Carlos Health Research Institute (IdISSC), Department of Neurology, San Carlos Clinical Hospital, Madrid, Spain.
Jorge Matias-GuiuLaboratory of Neurobiology and Advanced Therapies, Institute of Neurosciences, San Carlos Health Research Institute (IdISSC), Department of Neurology, San Carlos Clinical Hospital, Madrid, Spain.
Ulises Gómez-PinedoLaboratory of Neurobiology and Advanced Therapies, Institute of Neurosciences, San Carlos Health Research Institute (IdISSC), Department of Neurology, San Carlos Clinical Hospital, Madrid, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Organoids derived from stem cells have significantly advanced disease modeling, particularly in neurodegenerative disorders, while advancing personalized and regenerative medicine. These three-dimensional structures reproduce key aspects of human brain organization and functionality, while remaining simplified models that do not yet recapitulate full neural circuitry or disease progression, providing an improved platform for studying disease mechanisms, drug responses, and potential therapeutic strategies. This review explores the methodologies used in organoid development, including the differentiation of stem cells and culture techniques that enable the formation of self-organizing tissues. Organoids have been successfully used to model key cellular and molecular aspects of neurodegenerative diseases such as Alzheimer's and Parkinson's, offering insights into early disease mechanisms and potential novel treatment strategies. Key findings highlight that organoids provide more physiologically relevant data than traditional two-dimensional cultures and animal models, making them valuable tools for preclinical research and personalized treatment approaches. However, challenges remain, including variability in organoid generation, lack of vascularization, and difficulties in large-scale production for clinical applications. For the effective integration of organoids into biomedical and clinical applications, future research should prioritize improving reproducibility, standardization, and vascularization methods. Addressing these limitations will enhance their translational potential, leading to more effective treatments for neurodegenerative disorders and broader applications in precision medicine.

Indexed as

applicationsbrain organoidsdisease modelingneurodegenerative diseasespersonalized medicineregenerative medicinestem cells

Identifiers

PMID41278202
PMCPMC12631289

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.